Non-small cell lung cancer (NSCLC) is the most common type of lung cancer in the United States. It can cause a buildup of fluid around the lungs, known as pleural effusion. Roughly 80-85% of all lung ...
Leading Malignant Pleural Effusion companies in the market include - RS Oncology, Genelux Corporation, Candel Therapeutics, and others. The Malignant Pleural Effusion Market is projected to experience ...
Introduction Malignant pleural effusion (MPE) affects up to 15% of patients with cancer, and its incidence and prevalence are increasing. 1 - 4 Most cases are symptomatic; the most common symptoms are ...
For the diagnosis of people with pleural effusion, an initial image-assisted Abrams needle biopsy (IA-ANPB) can match medical thoracoscopy (MT) in diagnostic accuracy in some cases, a small randomized ...
The Key Malignant Pleural Effusion Companies in the market include - Genelux Corporation, RS Oncology, Canderl Therapeutics, Abnoba Korea, Jiangsu Simcere Pharmaceutical, Novartis, and others.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results